Aurobindo Pharma subsidiary faces 11 US FDA observations, company assures no financial impact

• US FDA inspected Aurobindo Pharma's wholly-owned subsidiary Eugia Pharma Specialities Ltd's Unit-III.
• The inspection, from January 27 to February 6, 2026, concluded with 11 procedural observations.
• Aurobindo Pharma stated the observations are procedural and will be addressed within the stipulated time.
• The company confirmed no impact on its financials or operations due to the inspection outcome.
• This follows a previous US FDA inspection of another subsidiary, Apitoria Pharma, which also resulted in procedural observations.